Tokyo Tape
Sign in
← Nipro

Quarterly report · Q2

8086.TEDINET S100PL3A
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
MetricValuePeriodScopeSource row
Revenue¥260.3bn2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥494.8bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥242.1bn2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥6.4bn2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥12.9bn2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥11.6bn2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥27.6bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥12.4bn2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥13.1bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥12.1bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥6.3bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥13.5bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥7.3bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥7.1bn2022-04-01 → 2022-09-30Cons.Profit loss
Net income¥8.1bn2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥1.01Tat 2022-09-30Cons.Assets
Total assets¥930.3bnat 2022-03-31Cons.Assets
Total assets¥888.3bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥768.6bnat 2022-09-30Cons.Liabilities
Total liabilities¥730.5bnat 2022-03-31Cons.Liabilities
Net assets / equity¥237.2bnat 2022-09-30Cons.Net assets
Net assets / equity¥199.9bnat 2022-03-31Cons.Net assets
Net assets / equity¥190.8bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥95.5bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥95.3bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥89.9bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥90.1bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥75.0bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥85.8bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥3.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥68.2bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥25.5bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥41.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥78.4bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥47.4bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥23.8bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥10.3bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥7.3bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥38.342022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥5.992022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥82.52021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥44.782021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥24.542021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥33.972022-04-01 → 2022-09-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥77.422021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥44.652021-04-01 → 2021-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio22.0%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio19.9%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio19.9%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-09-30¥2.1bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-09-30¥340m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-09-30¥1.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-09-30¥168m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥18.6bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥18.6bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥15.3bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue2022-04-01 → 2022-09-30¥203.9bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue external2022-04-01 → 2022-09-30¥200.8bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3.1bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentsegment profit2022-04-01 → 2022-09-30¥18.6bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue2022-04-01 → 2022-09-30¥44.9bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue external2022-04-01 → 2022-09-30¥34.1bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥10.8bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentsegment profit2022-04-01 → 2022-09-30¥849m
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue2022-04-01 → 2022-09-30¥28.0bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue external2022-04-01 → 2022-09-30¥25.0bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3.0bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentsegment profit2022-04-01 → 2022-09-30¥2.1bn
—segment totalrevenue2022-04-01 → 2022-09-30¥276.8bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥260.0bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥16.8bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥21.5bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥278.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥260.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥18.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥21.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-04-01 → 2021-09-30¥1.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-04-01 → 2021-09-30¥295m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-04-01 → 2021-09-30¥988m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-04-01 → 2021-09-30¥205m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥17.6bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥17.6bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥11.7bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue2021-04-01 → 2021-09-30¥186.8bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue external2021-04-01 → 2021-09-30¥183.4bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥3.3bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentsegment profit2021-04-01 → 2021-09-30¥19.6bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue2021-04-01 → 2021-09-30¥45.2bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue external2021-04-01 → 2021-09-30¥35.0bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥10.2bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentsegment profit2021-04-01 → 2021-09-30¥2.6bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue2021-04-01 → 2021-09-30¥26.5bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue external2021-04-01 → 2021-09-30¥23.4bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥3.1bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentsegment profit2021-04-01 → 2021-09-30¥2.1bn
—segment totalrevenue2021-04-01 → 2021-09-30¥258.4bn
—segment totalrevenue external2021-04-01 → 2021-09-30¥241.8bn
—segment totalrevenue intersegment2021-04-01 → 2021-09-30¥16.6bn
—segment totalsegment profit2021-04-01 → 2021-09-30¥24.3bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-09-30¥259.7bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-09-30¥242.1bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-09-30¥17.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-09-30¥24.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 643
ItemContextValueUnit
Net defined benefit liabilityCurrentQuarterInstant5872000000JPY
Provision for directors retirement benefitsPrior1YearInstant697000000JPY
Provision for directors retirement benefitsCurrentQuarterInstant649000000JPY
Provision for share based remuneration for directors and other officers nclPrior1YearInstant11000000JPY
Provision for share based remuneration for directors and other officers nclCurrentQuarterInstant17000000JPY
Provision for loss on litigation nclPrior1YearInstant102000000JPY
Provision for loss on litigation nclCurrentQuarterInstant135000000JPY
Other nclPrior1YearInstant8893000000JPY
Other nclCurrentQuarterInstant8937000000JPY
Noncurrent liabilitiesPrior1YearInstant418460000000JPY
Noncurrent liabilitiesCurrentQuarterInstant434855000000JPY
LiabilitiesPrior1YearInstant730453000000JPY
LiabilitiesCurrentQuarterInstant768561000000JPY
Capital stockPrior1YearInstant84397000000JPY
Capital stockCurrentQuarterInstant84397000000JPY
Retained earningsPrior1YearInstant94667000000JPY
Retained earningsCurrentQuarterInstant98336000000JPY
Treasury stockPrior1YearInstant-10748000000JPY
Treasury stockCurrentQuarterInstant-10748000000JPY
Shareholders equityPrior1YearInstant168316000000JPY
Shareholders equityCurrentQuarterInstant171985000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant9789000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant8127000000JPY
Deferred gains or losses on hedgesPrior1YearInstant-108000000JPY
Deferred gains or losses on hedgesCurrentQuarterInstant-85000000JPY
Foreign currency translation adjustmentPrior1YearInstant6885000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant40239000000JPY
Remeasurements of defined benefit plansPrior1YearInstant356000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant757000000JPY
Valuation and translation adjustmentsPrior1YearInstant16922000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant49040000000JPY
Non controlling interestsPrior1YearInstant14628000000JPY
Non controlling interestsCurrentQuarterInstant16132000000JPY
Net assetsPrior1YearInstant199867000000JPY
Net assetsCurrentQuarterInstant237158000000JPY
Liabilities and net assetsPrior1YearInstant930321000000JPY
Liabilities and net assetsCurrentQuarterInstant1005719000000JPY
Net salesPrior1YTDDuration242120000000JPY
Net salesCurrentYTDDuration260339000000JPY
Cost of salesPrior1YTDDuration168415000000JPY
Cost of salesCurrentYTDDuration181475000000JPY
Gross profitPrior1YTDDuration73704000000JPY
Gross profitCurrentYTDDuration78863000000JPY
Selling general and administrative expensesPrior1YTDDuration60841000000JPY
Selling general and administrative expensesCurrentYTDDuration72492000000JPY
Operating incomePrior1YTDDuration12863000000JPY
Operating incomeCurrentYTDDuration6371000000JPY
Interest income noiPrior1YTDDuration395000000JPY
Interest income noiCurrentYTDDuration484000000JPY
Dividends income noiPrior1YTDDuration601000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass